IDH3A and glioblastoma: In the 2021 WHO tumor classification, the existence of the isocitrate dehydrogenase (IDH 1/2) enzyme mutation is what distinguishes astrocytoma from GBM, further highlighting the clinical role of 2-hydroxyglutarate (2-HG) MRS [145].